Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
AAPS PharmSciTech ; 25(5): 112, 2024 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-38744715

RESUMO

This study aimed to develop a propellant-free topical spray formulation of Etodolac (BCS-II), a potent NSAID, which could be beneficial in the medical field for the effective treatment of pain and inflammation conditions. The developed novel propellant-free spray formulation is user-friendly, cost-effective, propellant-free, eco-friendly, enhances the penetration of Etodolac through the skin, and has a quick onset of action. Various formulations were developed by adjusting the concentrations of different components, including lecithin, buffering agents, film-forming agents, plasticizers, and permeation enhancers. The prepared propellant-free spray formulations were then extensively characterized and evaluated through various in vitro, ex vivo, and in vivo parameters. The optimized formulation exhibits an average shot weight of 0.24 ± 0.30 ml and an average drug content or content uniformity of 87.3 ± 1.01% per spray. Additionally, the optimized formulation exhibits an evaporation time of 3 ± 0.24 min. The skin permeation study demonstrated that the permeability coefficients of the optimized spray formulation were 21.42 cm/h for rat skin, 13.64 cm/h for mice skin, and 18.97 cm/h for the Strat-M membrane. When assessing its potential for drug deposition using rat skin, mice skin, and the Strat-M membrane, the enhancement ratios for the optimized formulation were 1.88, 2.46, and 1.92, respectively against pure drug solution. The findings from our study suggest that the propellant-free Etodolac spray is a reliable and safe topical formulation. It demonstrates enhanced skin deposition, and improved effectiveness, and is free from any skin irritation concerns.


Assuntos
Administração Cutânea , Etodolac , Absorção Cutânea , Pele , Animais , Etodolac/administração & dosagem , Etodolac/farmacocinética , Etodolac/química , Ratos , Camundongos , Absorção Cutânea/fisiologia , Pele/metabolismo , Pele/efeitos dos fármacos , Masculino , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/farmacocinética , Dor Aguda/tratamento farmacológico , Química Farmacêutica/métodos , Permeabilidade , Ratos Sprague-Dawley , Composição de Medicamentos/métodos
2.
Curr Pharm Des ; 29(21): 1645-1658, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37550904

RESUMO

This article explores the significant impact of artificial intelligence (AI) and machine learning (ML) on the pharmaceutical industry, which has transformed the drug development process. AI and ML technologies provide powerful tools for analysis, decision-making, and prediction by simplifying complex procedures from drug design to formulation design. These techniques could potentially speed up the development of better medications and drug development processes, improving the lives of millions of people. However, the use of these techniques requires trained personnel and human surveillance for AI to function effectively, if not there is a possibility of errors like security breaches of personal data and bias can also occur. Thus, the present review article discusses the transformative power of AI and ML in the pharmaceutical industry and provides insights into the future of drug development and patient care.


Assuntos
Inteligência Artificial , Aprendizado de Máquina , Humanos , Desenho de Fármacos , Desenvolvimento de Medicamentos , Indústria Farmacêutica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA